Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jason S Lewis

Showing results (201-210 of 359) with videos related to

Pageof 36
Sort By:
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 20, 2025
Radiolabeling of CHX-A″-DTPA-Antibody Conjugates with [<sup>89</sup>Zr]ZrCl<sub>4</sub>Serge K Lyashchenko, Tullio V Esposito, Tuan Tran, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 15, 2026
Exploring the 89 Zr/ 177 Lu Theranostic Pairing with an Extracellular Matrix Targeted Radiopharmaceutical Against Triple Negative Breast CancerJustin Hachey, Tara D Viray, Sebastian E Carrasco, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 18, 2017
First-in-Human Human Epidermal Growth Factor Receptor 2-Targeted Imaging Using <sup>89</sup>Zr-Pertuzumab PET/CT: Dosimetry and Clinical Application in Patients with Breast CancerGary A Ulaner, Serge K Lyashchenko, Christopher Riedl, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 9, 2023
<sup>212</sup>Pb-Pretargeted Theranostics for Pancreatic CancerDavid Bauer, Lukas M Carter, Mohamed I Atmane, et al.
Molecular Pharmaceutics|January 5, 2016
Applying ⁸⁹Zr-Transferrin To Study the Pharmacology of Inhibitors to BET Bromodomain Containing ProteinsMichael G Doran, Kathryn E Carnazza, Jeffrey M Steckler, et al.
Bioconjugate Chemistry|November 5, 2013
(18)F-labeled-bioorthogonal liposomes for in vivo targetingFabien Emmetiere, Christopher Irwin, Nerissa Therese Viola-Villegas, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 14, 2024
Interrogating the Theranostic Capacity of a MUC16-Targeted Antibody for Ovarian CancerKyeara N Mack, Zachary V Samuels, Lukas M Carter, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 4, 2016
Preclinical 89Zr Immuno-PET of High-Grade Serous Ovarian Cancer and Lymph Node MetastasisSai Kiran Sharma, Kuntal K Sevak, Sebastien Monette, et al.
Cancer Research|April 8, 2017
Multinuclear NMR and MRI Reveal an Early Metabolic Response to mTOR Inhibition in SarcomaValentina Di Gialleonardo, Hannah N Aldeborgh, Vesselin Miloushev, et al.
Molecular Cancer Therapeutics|February 8, 2022
Noninvasive Imaging of CD4+ T Cells in Humanized MiceVeronica L Nagle, Charli Ann J Hertz, Kelly E Henry, et al.
Pageof 36

Showing results (201-210 of 359) with videos related to

Sort By:
Pageof 36
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 20, 2025
Radiolabeling of CHX-A″-DTPA-Antibody Conjugates with [<sup>89</sup>Zr]ZrCl<sub>4</sub>Serge K Lyashchenko, Tullio V Esposito, Tuan Tran, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 15, 2026
Exploring the 89 Zr/ 177 Lu Theranostic Pairing with an Extracellular Matrix Targeted Radiopharmaceutical Against Triple Negative Breast CancerJustin Hachey, Tara D Viray, Sebastian E Carrasco, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 18, 2017
First-in-Human Human Epidermal Growth Factor Receptor 2-Targeted Imaging Using <sup>89</sup>Zr-Pertuzumab PET/CT: Dosimetry and Clinical Application in Patients with Breast CancerGary A Ulaner, Serge K Lyashchenko, Christopher Riedl, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 9, 2023
<sup>212</sup>Pb-Pretargeted Theranostics for Pancreatic CancerDavid Bauer, Lukas M Carter, Mohamed I Atmane, et al.
Molecular Pharmaceutics|January 5, 2016
Applying ⁸⁹Zr-Transferrin To Study the Pharmacology of Inhibitors to BET Bromodomain Containing ProteinsMichael G Doran, Kathryn E Carnazza, Jeffrey M Steckler, et al.
Bioconjugate Chemistry|November 5, 2013
(18)F-labeled-bioorthogonal liposomes for in vivo targetingFabien Emmetiere, Christopher Irwin, Nerissa Therese Viola-Villegas, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 14, 2024
Interrogating the Theranostic Capacity of a MUC16-Targeted Antibody for Ovarian CancerKyeara N Mack, Zachary V Samuels, Lukas M Carter, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 4, 2016
Preclinical 89Zr Immuno-PET of High-Grade Serous Ovarian Cancer and Lymph Node MetastasisSai Kiran Sharma, Kuntal K Sevak, Sebastien Monette, et al.
Cancer Research|April 8, 2017
Multinuclear NMR and MRI Reveal an Early Metabolic Response to mTOR Inhibition in SarcomaValentina Di Gialleonardo, Hannah N Aldeborgh, Vesselin Miloushev, et al.
Molecular Cancer Therapeutics|February 8, 2022
Noninvasive Imaging of CD4+ T Cells in Humanized MiceVeronica L Nagle, Charli Ann J Hertz, Kelly E Henry, et al.
Pageof 36